



POSTER

# Selection of anti-epileptic drugs in the initial phase of the treatment of epilepsy

O. Mostovaya<sup>1</sup>

Special Issue on Controversies in Neurology. From the 10<sup>th</sup> World Congress on Controversies in Neurology (CONy), Lisbon, Portugal. 17–20 March 2016.

## Abstract

The problem of choice of antiepileptic treatment is the ambiguity of the proposed options. Therefore, in our clinic, we have developed a system EEG - control the selection of drugs.

It is the following algorithm: (1) Night video monitoring with the daily record and conducting trial before and after sleeping, (2) The analysis conducted by the EEG and the choice of the segment that contains the abnormal patterns, (3) Appointment of anti-epileptic drugs from a first-line choice in the order, as proposed in the protocols followed by the EEG—a test action of the preparation on the selected segment of EEG (usually – it is 3 drugs), (4) The choice of the drug on the basis of a concrete manifestation of the effectiveness.

Clinical example: Patient Ch, Man/ 30 years old; epileptic seizures from he was 2 years old; he was treated by carbamazepine, valproate; episodically recently become frequent bouts; constantly have a headache; at this time, no drugs does not accept; seizures generalized tonic-clonic, 3 times a month; MRI without pathology.

Could the patient be cured if he was treated consistently? Figures 1–3 illustrate the follow-up of this patient.

The selection of AEDs in the beginning stage of long-term treatment of epilepsy should be carried out with the help of EEG control.




Figure 1. 14.09.2015.

<sup>1</sup>Psychiatrist, Dr, Ukraine

Correspondence: omostovaya@gmail.com




Figure 2. 22.09.2015 (levetiracetam).

Citation: Mostovaya et al. Selection of anti-epileptic drugs in the initial phase of the treatment of epilepsy. International Journal of Clinical Neurosciences and Mental Health 2016; 3(Suppl. 1):P100

Published: 16 March 2016



Open Access Publication Available at <http://ijcnmh.arc-publishing.org>

© 2016 Mostovaya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.






Figure 3. 29.09.2015 (lamotrigine 100).